OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

OCRF Talks

Q&A with Selvendiran Karuppaiyah, PhD

Dr. Selvendiran Karuppaiyah is a 2011 Liz Tilberis Grant Recipient. In this interview with OCRF’s Sarah DeFeo, Dr. Karuppaiyah discusses his research and what it means to receive a grant from OCRF. Sarah DeFeo:  Tell us how you became interested in being an ovarian cancer researcher. Selvendiran... 

OCRF Talks Q & A with Joanna Burdette, PhD.

Dr. Joanna Burdette is a 2011 Liz Tilberis Grant Recipient. In this interview with OCRF’s Sarah DeFeo, Dr. Burdette discusses her research and what it means to receive a grant from OCRF. Sarah DeFeo:  Tell us how you become interested in ovarian cancer research? Joanna Burdette:  My interest... 

Q&A with Tsz-Lun Yeung, Ph.D.

Dr. Tsz-Lun Yeung, Ph.D. is a 2011 Ann Schreiber Program of Excellence Grant Recipient. Sarah DeFeo: You were educated in Hong Kong. How did you end up doing research at MD Anderson Cancer Center in Houston? Tsz-Lun Yeung: I became interested in science in high school, and then studied molecular biology... 

Q&A with Sarah Adams, M.D., 2011 Liz Tilberis Awardee

Dr. Sarah Adams is a 2011 Liz Tilberis Grant Recipient. Sarah DeFeo: How did you end up becoming a gynecologic oncologist? Sarah Adams: Like many people, I didn’t always know this is what I wanted to do.  After college, I did volunteer work with AmeriCorps.  I was committed to service, and became... 

2011 SGO News: GI Risk Clarified for Bevacizumab

Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed. Treatment with bevacizumab was associated... 

2011 SGO News: Genetic Test May Spot Increased Risk for Inherited Ovarian Cancer

Nearly one in four ovarian cancers are inherited, say researchers who are developing a gene-based blood test to identify women with these hereditary cancers. The test, which looks for variations in 22 genes known or suspected to predispose women to ovarian cancer, isn’t ready for prime time yet. But... 

2011 SGO News: Menopause Symptoms Common after Gynecologic Cancer

Most survivors of gynecologic cancers have menopausal symptoms, and at least one in four takes replacement hormones, results of the first study of its kind showed. A survey of 544 gynecologic cancer survivors showed that 80% had one or more menopausal symptoms, investigators reported here at the Society... 

2011 SGO News: Mutation Link to Ovarian Cancer Disputed

  2011 SGO News: Mutation Link to Ovarian Cancer Disputed Developers of a genetic-susceptibility test for ovarian cancer might have jumped the gun, according to an OCRF-funded consortium that found no association between a KRAS mutation and risk of the cancer. Analysis of genetic information... 

2011 SGO News: ESAs Linked to Mortality Risk in Ovarian Cancer

Cancer recurrence and death occurred significantly more often in ovarian cancer patients treated with erythropoietin-stimulating agents (ESAs), data from a retrospective cohort review showed. ESA treatment also was associated with a briefer progression-free survival (PFS) and reduced overall survival,... 

2011 SGO News: PARP Inhibitor Active in Ovarian Cancer

Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed. Of 39 evaluable patients, 10 had partial responses and eight others had stable disease for a minimum of 12 weeks. The two groups combined had a clinical...